879562-26-2

• 常用中文名：4-(1-甲基乙烯)-2-丙基-1-[[2-(2H-四zol-5-基)[1,1-联苯]-4-基]甲基]-1H-咪唑-5-羧酸(5-甲基-2-氧代-1,3-二氧代l-4-基)甲酯
• 常用英文名：Olmesartan medoxomil impurity C
• CAS号：879562-26-2
• 分子式：C₂₉H₂₈N₆O₅
• 分子量：540.57000
• 相关类别： 信号通路 G 蛋白偶联受体/G 蛋白 血管紧张素受体
• 发布时间：2018-10-10 20:38:36
• 更新时间：2026-07-02 07:30:13
• Olmesartan medoxomil impurity C 是Olmesartan medoxomil 的杂质。Olmesartan medoxomil 是一种有效的选择性的 血管紧张素 (angiotensin AT1) 受体抑制剂,IC50 为 66.2 μM。

名称

• 中文名: 4-(1-甲基乙烯)-2-丙基-1-[[2-(2H-四zol-5-基)[1,1-联苯]-4-基]甲基]-1H-咪唑-5-羧酸(5-甲基-2-氧代-1,3-二氧代l-4-基)甲酯
• 英文名: (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-prop-1-en-2-yl-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
• 中文别名: 1-[[2'-(5-四唑基)-4-联苯基]甲基]-4-(1-丙烯-2-基)-2-丙基咪唑-5-甲酸((5-甲基-2-氧代-1,3-二噁茂-4-基)甲基)酯; OLMESTAN杂质3(奥美沙坦酯杂质C); 奥美沙坦酯杂质I; 奥美沙坦酯RNH-6373; 4-(1-甲基乙烯基)-2-丙基-1-[[2'-(2H-四唑-5-基)[1,1'-联苯]-4-基] 甲基]-1H-咪唑-5-羧酸,(5-甲基-2-氧代-1,3-二氧六环-4-基) 甲酯; 奥美沙坦酯杂质; 奥美沙坦酯杂质C; 奥美沙坦甲氧菊杂质C; 4-(1-甲基乙烯)-2-丙基-1-[[2-(2H-四ZOL-5-基)[1,1-联苯]-4-基]甲基]-1H-咪唑-5-羧酸(5-甲基-2-氧代-1,3-二氧代L-4-基)甲酯; (5-甲基-2-氧代-1,3-二氧杂-4-基)甲基1-((2'-(2H-四唑-5-基)-[1,1'-联苯] -4-基) 甲基)-4-(丙-1-烯-2-基)-2-丙基-1H-咪唑; OLMESTAN MEDOXOMIL 杂质 C; 脱氢奥美沙坦美多酯; (5-甲基-2-氧代-1,3-二氧杂-4-基)甲基 1-((2'-(2H-四唑-5-基)-[1,1'-联苯]-4-基)甲基)-4-(丙-1-烯-2-基)-2-丙基-1H-咪唑-5-羧酸酯; 美沙坦酯杂质C; 奥美沙坦酯杂质02; 奥美沙坦杂质I; (5-甲基-2-氧代-1,3-二氧代-4-基)甲基 1-((2'-(2H-四唑-5-基)-[1,1'-联苯]-4-基)甲基)-4-(丙-1-烯-2-基)-2-丙基-1H-咪唑-5-羧酸酯; 奥美沙坦杂质C; 奥美沙坦酯杂质C RNH-6373
• 英文别名: Olmestan Medoxomil Olefinic Impurity; olmesartan medoxomil dehydrate; Olmestan Medoxomil Impurity C, RNH-6373; OlMestan MedoxoMil IMpurity C (Dehydro IMpurity); 4-(1-Methylethenyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-Imidazole-5-cboxylic acid(5-methyl-2-oxo-1,3-dioxol-4-yl)methylester; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(1-Methylethenyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole-5-cboxylate; 4-(1-Methylethenyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]; Olmestan medoxomil impurity Ⅰ; Olmestan ester impurity C; DES(1-hydroxy-1-methylethyl)-(1-methylethenyl)-olmestan medoxomil; Olmestan Impurity 3(Olmestan Medoxomil Impurity C); Anhydro Olmestan Medoxomil; Olmestan Medoxomil Impurity D(Olmestan Medoxomil Impurity C); Olmestan imp C; Olmestan Medoxomil Impurity C (Dehydro Impurity), RNH-6373; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-prop-1-en-2-yl-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-cboxylate; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(1-Methylethenyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)bipheny; Dehydro Olmesartan Medoxomil; Olmestan impuirty C; 1H-Imidazole-5-cboxylic acid, 4-(1-methylethenyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl) -[1,1'-biphenyl]-4-yl)methyl)-4-(prop-1-en-2-yl)-2-propyl-1H-imidaze -5-cboxylate; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-[[2’-(5-Tetrazolyl)-4-biphenylyl]methyl]-4-(1-propen-2-yl)-2-propylimidazole-5-cboxylate; Olmestan Medoxomil impurity 12/Olmestan Medoxomil Impurity C/Dehydro Olmestan Medoxomil/(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2-(2H-tetrazol-5-yl)-[1,1-biphenyl]-4-yl)methyl)-4-(prop-1-en-2-yl)-2-propyl-1H-imidazole-5-cboxylate; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(prop-1-en-2-yl)-2-propyl-1H-imidazole-5-cboxylate; Olmestan Medoxomil-3; Olmestan Medoxomil Impurity RNH-6270（4-（1-hydroxy-1-methylethyl）-2-propyl-1-[[2’-（1H-tetrazol-5-yl）biphenyl-4-yl]methyl]-1H-imidazole-5-cboxylic acid）; Olmestan Medoxomil Dehydro; OlMestan MedoxoMil iMpurity I; Olmestan Medoxomil Impurity D; Olmestan Impurity C/ Olmestan Medoxomil Olefinic Impurity (Dehydro Olmestan Medoxomil/ Anhydro Olmestan Medoxomil); OlMestan IMpurity C; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(prop-1-en-2-yl)-2-propyl-1H-imidazole-5-cboxylate; Azilstan medoxomil impurity239; OlMestan IMp C (Dehydro OlMestanMedoxoMil) (OlMestan Styrene) (OlMestenOlefin); Olmestan Impurity C Dehydro Olmestan Medoxomil; 4-(1-Methylethenyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-cboxylic acid(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; 4-(1-methylethenyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-Imidazole-5-cboxylic acid(5-methyl-2-oxo-1,3-dioxol-4-yl)methy; Olmestan Medoxomil Impurity C; 4-(1-Methylethenyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'; (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL 1-((2-(2H-TETRAZOL-5-YL)-[1,1-BIPHENYL]-4-YL)METHYL)-4-(PROP-1-EN-2-YL)-2-PROPYL-1H-IMIDAZOLE-5-CBOXYLATE; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl] -4-yl)methyl)-4; Olmestan Medoxomilum Impurity C; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(pro; UNII-227N84S103

物化性质

• 分子式: C₂₉H₂₈N₆O₅
• 分子量: 540.57000
• 精确质量: 540.21200
• PSA: 141.93000
• LogP: 4.97570
• 储存条件: 室温，密闭，干燥

生物活性

• 描述: Olmesartan medoxomil impurity C 是Olmesartan medoxomil 的杂质。Olmesartan medoxomil 是一种有效的选择性的 血管紧张素 (angiotensin AT1) 受体抑制剂,IC50 为 66.2 μM。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 血管紧张素受体
  研究领域 >> 代谢疾病
• 参考文献:

  [1]. Senda A, et al. Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8. Biol Pharm Bull. 2015;38(12):1975-9.

  [2]. Shah S, et al. Simultaneous Quantitative Analysis of Olmesartan Medoxomil and Amlodipine Besylate in Plasma by High-performance Liquid Chromatography Technique. J Young Pharm. 2012 Apr;4(2):88-94.

合成路线

144689-63-4 ~% 879562-26-2

文献：EP2426126 A1, ; Page/Page column 10-11 ;

1227626-51-8 ~88% 879562-26-2

文献：Babu, Karrothu Srihari; Tagore, Amirisetty Ravindranath; Reddy, Gade Srinivas; Venkateswarlu, Gandu; Reddy, Padi Pratap; Anand, Ramasamy Vijaya Arkivoc, 2010 , vol. 2010, # 2 p. 292 - 302

上下游产品

上游产品  2
144689-63-4 1227626-51-8
下游产品  0